RedHill Biopharma (RDHL) Finished Goods (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Finished Goods for 3 consecutive years, with $2.8 million as the latest value for Q4 2024.

  • Quarterly Finished Goods fell 14.96% to $2.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2024, down 14.96% year-over-year, with the annual reading at $2.8 million for FY2024, 14.96% down from the prior year.
  • Finished Goods for Q4 2024 was $2.8 million at RedHill Biopharma, down from $3.3 million in the prior quarter.
  • The five-year high for Finished Goods was $6.8 million in Q4 2022, with the low at $2.8 million in Q4 2024.
  • Average Finished Goods over 3 years is $4.3 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Finished Goods crashed 51.25% in 2023, then dropped 14.96% in 2024.
  • Over 3 years, Finished Goods stood at $6.8 million in 2022, then plummeted by 51.25% to $3.3 million in 2023, then fell by 14.96% to $2.8 million in 2024.
  • According to Business Quant data, Finished Goods over the past three periods came in at $2.8 million, $3.3 million, and $6.8 million for Q4 2024, Q4 2023, and Q4 2022 respectively.